Anthem Biosciences launched its IPO on July 14, featuring an offer for sale of Rs 3,395 crore. The Bengaluru-based CRDMO, with a price band of Rs 540–570 per share, boasts integrated capabilities in both small and large molecules. Analysts recommend subscribing, citing its strong market position, revenue visibility, and high-margin business model.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets